Randomized, Single-dose, Crossover Study of 4 Decitabine and Tetrahydrouridine (EPI01) Formulations in Healthy Subjects (EPI01)

An Open-Label, Randomized, Single-Dose, Four-Way Crossover, Bioavailability Study of Three Formulations of Decitabine/Tetrahydrouridine (THU) Combination Modified Release Capsules (5 mg/250 mg) in Healthy and Fasting Adults

To study the pharmacokinetic profiles of decitabine and tetrahydrouridine (THU) from 3 modified release formulations in healthy subjects.

Study Overview

• Status: Completed
• Conditions: Healthy
• Intervention / Treatment: Drug: Decitabine

Detailed Description

This is an open-label, randomized, single-dose per period, four-period, crossover study to evaluate relative bioavailability of decitabine in three newly formulated THU and decitabine combination capsules in comparison to 3 capsules of THU followed 1 hour later by 3 capsules of decitabine.

• Study Type: Interventional
• Enrollment (Actual): 16
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Texas
    • San Antonio, Texas, United States, 78217
      • Worldwide Clinical Trial

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 50 years (ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

• Must understand and voluntarily sign a written ICF prior to any study related procedures being performed and be able to adhere to restrictions and examination schedules.
• Must be able to communicate with the investigator, and to understand and comply with the requirements of the study.
• Healthy male volunteers from any race between 18 to 50 years of age (inclusive), and in good health as determined by past medical history, physical examination, vital signs, ECG, and laboratory tests at screening.
• Must have a body mass index (BMI) between 18 and 30 kg/m2 (inclusive) and a weight between 60 and 100 kg (132 to 220 lb), inclusive, at screening.
• Subject's clinical laboratory test results have no clinically significant findings, in the opinion of the Investigator.
• Vital signs (systolic and diastolic blood pressure and pulse rate) will be assessed in the supine position after the subject has rested for at least 5 minutes. At screening, the potential subject must be afebrile, with a systolic blood pressure between 90 and 140 mmHg (inclusive), diastolic blood pressure between 60 and 90 mmHg (inclusive), and pulse rate between 50 and 100 bpm (inclusive). Vital signs criteria at each check-in and the pre-dose measurements will be at the Investigator's discretion.
• Subjects must be free of any clinically significant disease that would interfere with the study evaluations.
• Subjects (including those who have had a documented vasectomy) must be using a double-barrier local contraception (i.e., spermicidal gel plus condom) when engaging in sexual activity with women of childbearing potential while on study medication and for 28 days after the last dose of study medication.
• Subjects must refrain from sperm donations while on study drug, for the entire duration of the study, and for 28 days after the last dose of study drug.

Exclusion Criteria:

• History or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, oncologic, or psychiatric disease or any other condition, including the presence of laboratory abnormalities, that, in the opinion of the Investigator, would jeopardize the safety of the subject or the validity of the study results.
• Any serious medical condition, clinically significant laboratory abnormality, or psychiatric illness that would prevent the subject from signing the ICF.
• Recent history within 3 years of any clinically significant neurological, gastrointestinal, renal, hepatic, cardiovascular, psychological, pulmonary, metabolic, endocrine, hematological or other major disorders.
• Used any prescribed systemic or topical medication within 30 days of the first dose administration.
• Used any non-prescribed systemic (including herbal medicines, e.g. St. John's Wort) or topical medication within 7 days of the first dose administration (with the exception of vitamin/mineral supplements)
• Subjects who have any surgical or medical conditions possibly affecting drug absorption, distribution, metabolism and excretion (ADME).
• Exposed to an investigational drug (new chemical entity) within 90 days preceding the first dose administration or currently enrolled in any investigational trials.
• Donated blood or plasma within 8 weeks preceding the first dose administration.
• History of multiple drug allergies.
• Any clinically significant allergic disease (excluding nonactive hay fever).
• History of drug abuse of at least 2 years prior to dosing, or positive drug screening test due to illicit drugs.
• History of alcohol abuse of at least 2 years prior to dosing, or positive alcohol screen.
• Smokers or users of other tobacco products (e.g., chewing tobacco, or those using nicotine-containing products (i.e., patches, gum) in the 3 months prior to screening, or positive urine cotinine test.
• Known to have serum hepatitis or known to be a carrier of the hepatitis B surface antigen (HBsAg) or hepatitis C antibody, or tests positive for HIV (human immunodeficiency virus) antibodies at screening.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: OTHER
• Allocation: RANDOMIZED
• Interventional Model: CROSSOVER
• Masking: NONE

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Formulation A; 3 test capsules of combination decitabine/THU (5 mg/250 mg per capsule; Formulation A) given as a single oral dose with approximately 240 mL (8 fluid ounces) of ambient temperature water.	Drug: Decitabine; Combination drugs containing decitabine and tetrahydrouridine; Other Names: Tetrahydrouridine
EXPERIMENTAL: Formulation B; 3 test capsules of combination decitabine/THU (5 mg/250 mg per capsule; Formulation B) given as a single oral dose with approximately 240 mL (8 fluid ounces) of ambient temperature water.	Drug: Decitabine; Combination drugs containing decitabine and tetrahydrouridine; Other Names: Tetrahydrouridine
EXPERIMENTAL: Formulation C; 3 test capsules of combination decitabine/THU (5 mg/250 mg per capsule; Formulation C) given as a single oral dose with approximately 240 mL (8 fluid ounces) of ambient temperature water.	Drug: Decitabine; Combination drugs containing decitabine and tetrahydrouridine; Other Names: Tetrahydrouridine
ACTIVE_COMPARATOR: Reference Formulation; 3 capsules of THU (250 mg per capsule) given as a single oral dose with approximately 240 mL of ambient temperature water, followed by a single oral dose of 3 capsules of decitabine (5 mg per capsule) given 1 hour later with approximately 240 mL of ambient temperature water.	Drug: Decitabine; Combination drugs containing decitabine and tetrahydrouridine; Other Names: Tetrahydrouridine

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Decitabine plasma concentration	Maximum concentration (Cmax) of Decitabine in plasma	24 hours
Pharmacokinetics of Decitabine	Area under the concentration-time curve (AUC) from time of dosing to the last quantifiable concentration of Decitabine	24 hours
Pharmacokinetics of Tetrahydrouridine	Area under the concentration-time curve (AUC) from time of dosing to the last quantifiable concentration of THU	24 hours

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety of Decitabine and Tetrahydrouridine	Safety of single dose as measured by adverse event reporting	24 hours

Collaborators and Investigators

• Sponsor: EpiDestiny, Inc.
• Investigators: Principal Investigator: Cynthia A Zamora, MD, Worldwide Clinical Trials Early Phase Services, LLC

Publications and helpful links

Helpful Links

• To participate in a Worldwide clinical trial

Study record dates

Study Major Dates

• Study Start (ACTUAL): April 3, 2019
• Primary Completion (ACTUAL): May 2, 2019
• Study Completion (ACTUAL): May 3, 2019

Study Registration Dates

• First Submitted: January 31, 2019
• First Submitted That Met QC Criteria: January 31, 2019
• First Posted (ACTUAL): February 4, 2019

Study Record Updates

• Last Update Posted (ACTUAL): May 9, 2019
• Last Update Submitted That Met QC Criteria: May 7, 2019
• Last Verified: May 1, 2019

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antimetabolites, Antineoplastic; Antimetabolites; Antineoplastic Agents; Decitabine; Tetrahydrouridine
• Other Study ID Numbers: EPI-01-CP.001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED
• IPD Plan Description: Undecided

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No